Osteoporotic patients exhibited better improvements with the treatment comprising nitrogen bisphosphonates, evident from an observational study of 6120 participants aged 50+ published in the Journal of Osteoporosis International. The aim of this analysis was to assess the relationship between various classes of BP and mortality risk among people with or without a fracture.

Users of different BPs resembled with non-users by propensity score (gender, age, fragility fracture status, co-morbidities) and with the time to initiating BP medicine from the population-based Canadian Multicentre Osteoporosis Study. Mortality risk between BP users and matched non-users were evaluated by applying the multivariable Cox proportional hazards models.

The BP group comprised 308 men and 2048 women and non-users group comprised 1794 men and 1970 women. The association between mortality risk and BP was assessed in three different 1:1 propensity score-matched cohorts (Etidronate, Risedronate, and Alendronate) of BP users and non-users. Further, the rates of mortality were lower and within patients used Nitrogen BP (n-BP) (Alendronate and Risedronate) as compared to non-n-BP (Etidronate). The n-BP also exhibited a better survival as compared to the non-n-BP. As per these findings, as compared to no treatment, nitrogen bisphosphonates exhibited better survival and lower mortality rates.